Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expiration Fourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00 Fourth quarter non-GAAP operating earnings...
Related Questions
How does Cardinal Health's FY2025 performance compare to its main competitors in the pharmaceutical distribution and services sector?
What are the assumptions behind the FY2026 guidance and how likely are they to be met?
How will the guidance affect analyst sentiment and target price revisions?
How will the flat Q4 revenue and the 21% growth excluding the contract expiration impact the stock price in the near term?
What does the guidance for FY2026 imply about future earnings growth and valuation multiples?
How does Cardinal Health's Q4 GAAP operating earnings of $428 million compare to consensus expectations and analyst estimates?
What are the key drivers behind the GAAP and non‑GAAP earnings differences, and are they sustainable?
What impact does the previously communicated contract expiration have on future revenue trends and margin stability?
What is the outlook for cash flow, capex, and debt levels given the current earnings profile?
Is there any guidance on dividend policy or share buyback plans in light of the earnings results?
What macro‑economic or regulatory risks could affect the company's guidance and performance?